Crescent Innovations Inc. Reports That Inquiries Surrounding Sale of Its Bone Repair Technology Are Increasing
August 29, 2024 08:00 ET | Crescent Innovations Inc.
Crescent Innovations Inc. reports that inquires surrounding sale of its bone repair technology are increasing.
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
May 13, 2024 08:00 ET | Compass Therapeutics
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment...
Compass-logo-RGB-outlines.png
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
April 12, 2024 08:00 ET | Compass Therapeutics
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
March 21, 2024 09:00 ET | Compass Therapeutics
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
roche-logo-blue.png
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
February 01, 2024 01:03 ET | F. Hoffmann-La Roche Ltd
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months...
Compass-logo-RGB-outlines.png
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
June 22, 2023 16:05 ET | Compass Therapeutics
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
logo color s and clearside.jpg
Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023
February 07, 2023 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Zhittya Logo.jpg
Zhittya Genesis Medicine announces: Free Zoom Webinar: Zhittya Parkinson’s Disease Research Study: 6-Month Patient Follow-Up Report
December 19, 2022 12:00 ET | Zhittya Genesis Medicine Inc
LAS VEGAS, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that they will be hosting a webinar on Tuesday, December 20, 2022, at 4:00 PM...
Zhittya Logo.jpg
Zhittya Genesis Medicine - Parkinson’s Disease and Other Brain Disorders: Is FGF-1 a Novel Breakthrough Medical Treatment
October 25, 2022 10:00 ET | Zhittya Genesis Medicine Inc
Invitation to a Free Luncheon Presentation in Jeddah, Saudi Arabia, on Monday, October 31, 2022, at 1:00 pm (13:00) View Preliminary Human Data after 30 Days Treatment of Parkinson’s Disease Patients...
Zhittya Logo.jpg
Zhittya Genesis Medicine announces: Free Zoom Webinar: Parkinson’s Disease Sufferers Motor Skills Improve by 50% After Medical Research Study
June 21, 2022 10:00 ET | Zhittya Genesis Medicine Inc
LAS VEGAS, June 21, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that they will be hosting a webinar on June 23, 2022 at 3:00 PM Pacific Time...